British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Elizabeth J. Price; Stuart Benjamin; Michele Bombardieri; Simon Bowman; Sara  Carty; Coziana Ciurtin; Bridget Crampton; Annabel Dawson; Benjamin A. Fisher; Ian Giles; Peter Glennon; Monica Gupta; Katie Hackett; Genevieve Larkin; Wan-Fai Ng; A.V. Ramanan; Saad Rassam; Saaeha Rauz; Smith Guy; Nurhan Sutcliffe; Anwar R. Tappuni; Stephen B. Walsh

doi:10.1093/rheumatology/keae152

British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Elizabeth J. Price^*, Stuart Benjamin, Michele Bombardieri, Simon Bowman, Sara Carty, Coziana Ciurtin, Bridget Crampton, Annabel Dawson, Benjamin A. Fisher, Ian Giles, Peter Glennon, Monica Gupta, Katie Hackett, Genevieve Larkin, Wan-Fai Ng, A.V. Ramanan, Saad Rassam, Saaeha Rauz, Smith Guy, Nurhan SutcliffeAnwar R. Tappuni, Stephen B. Walsh

^*Corresponding author for this work

Social Work, Education & Community Wellbeing

Research output: Contribution to journal › Article › peer-review

70 Downloads (Pure)

Abstract

Sjogren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL). Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individual to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity.

This guideline builds on, and widens the recommendations developed for the first guideline published in 2017. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK based rheumatology teams.

Original language	English
Article number	keae152
Pages (from-to)	1-31
Number of pages	31
Journal	Rheumatology
Early online date	16 Apr 2024
DOIs	https://doi.org/10.1093/rheumatology/keae152
Publication status	E-pub ahead of print - 16 Apr 2024

Keywords

Sjogren
sicca
treatment
management
guideline
recommendation
juvenile onset
adult onset

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rheumatology/keae152Licence: CC BY

Sjogren_s_guideline_2023_full_guideline_FINAL_revised_Feb_2024_CLEAN_002_Accepted author manuscript, 606 KBLicence: CC BY
keae152Final published version, 3.25 MBLicence: CC BY

Cite this

Price, E. J., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., Crampton, B., Dawson, A., Fisher, B. A., Giles, I., Glennon, P., Gupta, M., Hackett, K., Larkin, G., Ng, W-F., Ramanan, A. V., Rassam, S., Rauz, S., Guy, S., ... Walsh, S. B. (2024). British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology, 1-31. Article keae152. Advance online publication. https://doi.org/10.1093/rheumatology/keae152

@article{1a88c315c2e84feaa7ce2ec2c3e99a1e,

title = "British Society for Rheumatology guideline on management of adult and juvenile onset Sj{\"o}gren disease",

abstract = "Sjogren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL). Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individual to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK based rheumatology teams. ",

keywords = "Sjogren, sicca, treatment, management, guideline, recommendation, juvenile onset, adult onset",

author = "Price, {Elizabeth J.} and Stuart Benjamin and Michele Bombardieri and Simon Bowman and Sara Carty and Coziana Ciurtin and Bridget Crampton and Annabel Dawson and Fisher, {Benjamin A.} and Ian Giles and Peter Glennon and Monica Gupta and Katie Hackett and Genevieve Larkin and Wan-Fai Ng and A.V. Ramanan and Saad Rassam and Saaeha Rauz and Smith Guy and Nurhan Sutcliffe and Tappuni, {Anwar R.} and Walsh, {Stephen B.}",

year = "2024",

month = apr,

day = "16",

doi = "10.1093/rheumatology/keae152",

language = "English",

pages = "1--31",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press (OUP)",

}

Price, EJ, Benjamin, S, Bombardieri, M, Bowman, S, Carty, S, Ciurtin, C, Crampton, B, Dawson, A, Fisher, BA, Giles, I, Glennon, P, Gupta, M, Hackett, K, Larkin, G, Ng, W-F, Ramanan, AV, Rassam, S, Rauz, S, Guy, S, Sutcliffe, N, Tappuni, AR & Walsh, SB 2024, 'British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease', Rheumatology, pp. 1-31. https://doi.org/10.1093/rheumatology/keae152

TY - JOUR

T1 - British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

AU - Price, Elizabeth J.

AU - Benjamin, Stuart

AU - Bombardieri, Michele

AU - Bowman, Simon

AU - Carty, Sara

AU - Ciurtin, Coziana

AU - Crampton, Bridget

AU - Dawson, Annabel

AU - Fisher, Benjamin A.

AU - Giles, Ian

AU - Glennon, Peter

AU - Gupta, Monica

AU - Hackett, Katie

AU - Larkin, Genevieve

AU - Ng, Wan-Fai

AU - Ramanan, A.V.

AU - Rassam, Saad

AU - Rauz, Saaeha

AU - Guy, Smith

AU - Sutcliffe, Nurhan

AU - Tappuni, Anwar R.

AU - Walsh, Stephen B.

PY - 2024/4/16

Y1 - 2024/4/16

N2 - Sjogren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL). Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individual to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK based rheumatology teams.

AB - Sjogren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL). Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individual to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK based rheumatology teams.

KW - Sjogren

KW - sicca

KW - treatment

KW - management

KW - guideline

KW - recommendation

KW - juvenile onset

KW - adult onset

U2 - 10.1093/rheumatology/keae152

DO - 10.1093/rheumatology/keae152

M3 - Article

SN - 1462-0324

SP - 1

EP - 31

JO - Rheumatology

JF - Rheumatology

M1 - keae152

ER -